Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells

Not yet recruiting

• Conditions: Stem Cells; Chronic Kidney Diseases; Obesity; Diabetes type2
• Interventions: Biological: urine collection

• Registration Number: NCT04998461
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Obesity is at risk for the development of chronic kidney disease but the involved mechanisms are not known (Navarro et al. 2015). Establishing the link between obesity and kidney damage is difficult. Indeed, kidney function measurement lacks precision in obese people (Lemoine et al. 2014) and requires expensive methods such as measurement of 99mTc-DTPA clearance. Biopsies are too invasive for the detection of emerging kidney damage or for the following of the kidney function. Therefore new tools are required for the early identification of at risk individuals for the kidney damage complication.

Mesenchymal stem cells may represent such a relevant tool. These cells are present in a large number of organs, including kidney (Costa et al. 2020).

In addition to be differentiated cells progenitors (Dominici et al. 2006), they also support immunosuppressive, anti-fibrotic and pro-angiogenic functions that have been used for the treatment of kidney fibrosis (Usunier et al. 2014). Therefore, mesenchymal stem cells contribute to tissue homeostasis and their alterations may reflect organ dysfunctions. Indeed, mesenchymal stem cells from obese adipose tissue lose their immunosuppressive (Serena et al. 2016) and differentiation (Gustafson et al. 2009) functions and contribute to fibrosis (Keophiphath et al. 2009) and inflammation (Lee et al. 2010; Gustafson, Nerstedt, et Smith 2019). It is thus probable that kidney dysfunctions are associated with functional alterations of kidney mesenchymal stem cells.

The collection of mesenchymal stem cells from kidney can easily be performed from urine and next cultivated for amplification. They are called urine stem cells (USC).

From our experience with obese mouse adipose stem cells, we observed that functional changes of stem cells preceded adipose tissue dysfunctions. Functional signatures of mesenchymal stem cells are thus representative of changes occuring in the function of the tissue notably in answer to obesity. These features could be used to identify obese people presenting ongoing alterations of kidney function, before clinical manifestations of kidney dysfunction. Because kidney mesenchymal stem cells are easy to isolate from urine, their collection is compatible with the follow up of patients and can be applied to a large number of individuals, including the younger. USC could represent a valuable tool to detect progression towards kidney damage.

In this project we plan to analyse USC alterations induced by obesity and to identify signatures associated with the progression towards kidney damage and type 2 diabetes. The goal is to evaluate USC as potential marker for the non invasive monitoring of patients in answer to a need that is not achieved by the present available approaches.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2021-08
• Study First Submitted: 2021-08-02
• Study First Submitted QC: 2021-08-02
• Last Update Submitted: 2021-08-02
• Study First Posted: 2021-08-10
• Last Update Posted: 2021-08-10
• Study Start: 2021-11
• Primary Completion: 2025-05
• Study Completion: 2026-06

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Obese patients with normal renal function	urine collection	* estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2 * Body Mass Index (BMI) \> 30 kg/m2 * Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria \< 0.15 g/24h
Obese patients with impaired renal function	urine collection	* estimated Glomerular Filtration Rate (eDFG) \< 60 ml/min/1.73 m2 * Body Mass Index (BMI) \> 30 kg/m2 * Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria \< 0.15 g/24h
Non-obese patients with impaired renal function	urine collection	* estimated Glomerular Filtration Rate (eDFG) \< 60 ml/min/1.73 m2 * Body Mass Index (BMI) between 18 and 30 kg/m2 * Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria \< 0.15 g/24h
Non-obese patients with normal renal function (control group)	urine collection	* estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2 * Body Mass Index (BMI) between 18 and 30 kg/m2 * Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria \< 0.15 g/24h

Primary Outcome Measures

Name	Time	Method
Comparison of gene expression in USC (Urinary Stem Cells)	inclusion day	High throughput sequencing will be used to compare USC (Urinary Stem Cells) for the differential expression of genes between the 4 populations (obese or lean patients, with or without alteration of the kidney function). A gene set enrichment analysis will be used to identify the main functions supported by USC from each patient, establishing a signature.

Trial Locations

Locations (1)

Centre Hospitalier Lyon SUD; 🇫🇷 Pierre-Bénite, France